ABSTRACT
The ASPREE randomized controlled trial (2010-2017) of 19,114 community-dwelling older adults without cardiovascular disease and significant disability compared daily 100mg aspirin to placebo. A total of 16,317 (93%) of 17,546 surviving and non-withdrawn participants agreed to continue regular study follow-up visits in the post-trial phase, named ASPREE-XT (2017-2024). We present a statistical analysis plan to underpin three main papers to report aspirin effects through to the fourth post-trial ASPREE-XT study visit with focus areas of: (1) death, dementia, and disability, (2) CVD events and bleeding, and (3) cancer. The focus of the plan is to estimate long-term (entire timespan of RCT plus post-trial) and legacy (post-trial period only) effects of aspirin in the setting of primary prevention for older individuals. Preliminary insights to these effects are presented that are based on data that has been reported to the study’s observational study monitoring board however formal data lock is not expected until October 2023.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01038583
Clinical Protocols
https://aspree.org/aus/wp-content/uploads/sites/2/2021/05/ASPREE-XT-Protocol-v5-April-2021.pdf
Funding Statement
ASPREE was supported by U01AG029824 from the National Institute on Aging (NIA) and the National Cancer Institute (NCI) at the National Institutes of Health (NIH), as well as grants 334047 and 1127060 from the National Health and Medical Research Council of Australia (NHMRC), and additional funding from Monash University and the Victorian Cancer Agency. ASPREE-XT is supported by U19AG062682 from NIA and NCI.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Alfred Hospital Ethics Committee (ethics #HREC/17/Alfred/198) gave ethical approval for the ASPREE-XT project as the primary site approver. Human Research Ethics Committee (Tasmania) Network (ethics #H0017149) gave ethical approval for the ASPREE-XT project as a secondary site approver. Monash University Human Research Ethics Committee (ethics #12771) gave ethical approval for the ASPREE-XT project as a secondary site approver. ACT Health Human Research Ethics Committee (Canberra) (ethics #ETH.3.18.037E) gave ethical approval for the ASPREE-XT project as a secondary site approver. The University of Adelaide Human Research Ethics Committee (ethics #32802) gave ethical approval for the ASPREE-XT project as a secondary site approver. The University of Iowa single Institutional Review Board gave consent for ASPREE-XT annual visits under the single IRB of record.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Contact: Rory.Wolfe{at}monash.edu
Data Availability
All data produced in the present study are available upon reasonable request to the authors
